iSpecimen

iSpecimen Rule of 40

The Rule of 40 of iSpecimen (ISPC) as of Nov 4, 2026 is -544.66 %. In the previous year, Rule of 40 was -143.41 % — a change of 279.79% (lower).

Rule of 40

-544.66 %

YoY

279.79%

Last updated:

Rule of 40 of iSpecimen is 2025 -544.66 % . Rule of 40 of iSpecimen was 2024 -143.41 % . It decreases by 279.79% lower compared to the previous year.

The iSpecimen Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
-75.72 USD
Jan 1, 2020
59.17 USD
Jan 1, 2021
-25.54 USD
Jan 1, 2022
-104.41 USD
Jan 1, 2023
-117.06 USD
Jan 1, 2024
-143.41 USD
Jan 1, 2025
-544.66 USD
The iSpecimen Rule of 40 history
YEARRule of 40YoY
-544.66 %+279.79%
-143.41 %+22.51%
-117.06 %+12.11%
-104.41 %+308.84%
-25.54 %-143.16%
59.17 %-178.15%
-75.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iSpecimen Stock analysis

What does iSpecimen do? iSpecimen, Inc. generates revenue through its iSpecimen Marketplace platform, which connects healthcare providers with biospecimens to researchers in biopharmaceutical, in vitro diagnostic (IVD), and government/academic sectors. The platform consolidates biospecimen procurement by offering a single online marketplace where healthcare supply partners provide de-identified healthcare data, enabling researchers to search, manage workflows, and access administrative tools. Biopharmaceutical companies, IVD firms, and academic institutions purchase access to the platform’s data and services to accelerate medical discovery and streamline procurement processes. The company’s functional areas—search, workflow, data, and administration and reporting—support these transactions through integrated administrative and compliance management for all users. The iSpecimen Marketplace platform serves biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions by providing a centralized hub for biospecimen procurement. Healthcare providers supplying biospecimens use the platform to list their collections, while researchers from the target sectors access the data for their studies. The platform’s de-identified healthcare data, compiled from healthcare supply partners, is a key asset that drives transactions. Administrative and reporting functions within the platform streamline operations for both suppliers and researchers, reducing manual effort and improving compliance. iSpecimen, Inc. monetizes its platform by facilitating connections between biospecimen suppliers and researchers across biopharmaceutical, IVD, and academic sectors. The company’s revenue comes from transactions and services provided through the iSpecimen Marketplace, which includes search capabilities, workflow management, data access, and administrative support. Healthcare supply partners contribute de-identified healthcare data to the platform, which researchers use to identify and procure necessary biospecimens for medical research and development. iSpecimen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iSpecimen stock

Rule of 40 of iSpecimen is -544.66 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 iSpecimen since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — iSpecimen

All Key Metrics — iSpecimen